SCHEMBL2736840

SCHEMBL2736840

CCCCn1cc(-c2ccc3c(c2)OCO3)cc(C(=O)NCc2ccc(F)cc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 5/20 0.47
KMT2A Q03164 4/20 0.47
POLB P06746 2/20 0.47
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47
MAPK10 P53779 1/20 0.47
PKM P14618 1/20 0.47
MCL1 Q07820 1/20 0.47
HKDC1 Q2TB90 1/20 0.47
HPGD P15428 7/20 0.46
HTT P42858 2/20 0.46
USP2 O75604 2/20 0.46
KDM4E B2RXH2 3/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736837 0.91 CNR2 (0.51) CNR2LMNAMAPTALDH1A1KMT2A
SCHEMBL2736820 0.88 CNR1 (0.50) CNR2LMNAKMT2APOLBHPGD
SCHEMBL2736808 0.85 CNR1 (0.48) CNR2KMT2APOLBHPGDSMN1; SMN2
SCHEMBL2736854 0.84 CNR1 (0.48) CNR2LMNAMAPTALDH1A1KMT2A
SCHEMBL2736810 0.83 CNR2 (0.56) CNR2LMNAMAPTKMT2APOLB
SCHEMBL2736839 0.82 CNR2 (0.57) CNR2LMNAMAPTKMT2APOLB
SCHEMBL2736797 0.82 CNR1 (0.45) CNR2POLBHPGDSMN1; SMN2RAB9A
SCHEMBL2736849 0.82 CNR1 (0.48) CNR2LMNAMAPTKMT2APOLB
SCHEMBL2736879 0.82 NPC1 (0.48) CNR2ALDH1A1POLBKDM4ERAB9A
SCHEMBL2736894 0.82 FAAH (0.53) CNR2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R CNR2 1/4885LMNA 3511/4885MAPT 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.